Asarina Pharma AB (publ) Q4 / Year End 2020 report released
Asarina Pharma CEO Peter Nordkild: “2020 was a turbulent, challenging year for all of us - yet at Asarina Pharma we begin 2021 with continued confidence in the high potential of our flagship compound Sepranolone. We are on schedule to publish our topline results for our Phase IIa Menstrual Migraine study in June 2021, and in the same month initiate our Phase IIa study in Tourette syndrome.”FINANCIAL HIGHLIGHTS · R&D costs reflecting termination of PMDD and CMC activities · Staff costs lower due to headcount reduction · Solid cash position at year-end R&D HIGHLIGHTS